Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees

Human Vaccines & Immunotherapeutics
Sumathy VelumaniKatja Fink

Abstract

Globally, dengue virus (DENV) is one of the most widespread vector-borne viruses. Dengue disease affects populations in endemic areas and, increasingly, tourists who travel to these countries, but there is currently no approved vaccine for dengue. A phase 3 efficacy trial with Sanofi-Pasteur's recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) conducted in South East Asia showed an overall efficacy of 56% against virologically confirmed dengue infections of any severity and any of the 4 serotypes, but the long-term protection of the vaccine has yet to be demonstrated. To address longevity of antibody titers and B cell memory, we recalled study participants from an earlier CYD immunogenicity study (Phase 2) conducted in Singapore that enrolled healthy volunteers in the year 2009. Depending on the age group, 57-84% of the participants initially generated a neutralizing antibody titer ≥ 10 to all 4 DENV serotypes 28 d after the third and final dose. We observed very low antibody titers in blood samples collected from 23 vaccinees 5 y after the first dose, particularly titers of antibodies binding to virus particles compared with those binding to recombinant E protein. The in vivo efficacy of plasma antibodies again...Continue Reading

References

Nov 11, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Shane CrottyRafi Ahmed
Feb 25, 2006·Nature Reviews. Immunology·Lars HangartnerHans Hengartner
Nov 9, 2007·The New England Journal of Medicine·Ian J AmannaMark K Slifka
May 21, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nguyen Thi Phuong DungCameron P Simmons
Sep 21, 2011·The Journal of Infectious Diseases·Anuja MathewAlan L Rothman
Mar 14, 2012·PLoS Neglected Tropical Diseases·Hope H BiswasEva Harris
Nov 16, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Meihui XuKatja Fink
Dec 4, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tatiana M Garcia-BatesSimon M Barratt-Boyes
Mar 5, 2013·Journal of Immunological Methods·Maja JahnmatzNiklas Ahlborg
Apr 9, 2013·Nature·Samir BhattSimon I Hay
Apr 13, 2013·Proceedings of the National Academy of Sciences of the United States of America·Daniela WeiskopfAlessandro Sette
Jun 19, 2013·The Journal of Infectious Diseases·Sandra OlkowskiSteven T Stoddard
Aug 22, 2013·Current Opinion in Infectious Diseases·Stephen J Thomas, Timothy P Endy
May 2, 2014·Frontiers in Immunology·Raphaël M Zellweger, Sujan Shresta
Nov 5, 2014·The New England Journal of Medicine·Luis VillarUNKNOWN CYD15 Study Group
Feb 14, 2015·Nature Reviews. Immunology·Tomohiro KurosakiWataru Ise
Jul 28, 2015·The New England Journal of Medicine·Sri Rezeki HadinegoroUNKNOWN CYD-TDV Dengue Vaccine Working Group

❮ Previous
Next ❯

Citations

Mar 18, 2016·The Journal of Infectious Diseases·Brett M ForsheyAmy C Morrison
Jul 5, 2016·Frontiers in Immunology·Juan Carlos Yam-PucLeopoldo Flores-Romo
Aug 9, 2016·The Journal of Infectious Diseases·Annelies Wilder-SmithTerry Nolan
Aug 9, 2016·The Journal of Infectious Diseases·Scott B Halstead
Nov 15, 2018·The New England Journal of Medicine·Klara M Posfay-Barbe, Arnaud G L’Huillier
Nov 16, 2018·The New England Journal of Medicine·Mark K Slifka, Ian J Amanna
Aug 29, 2018·Journal of Biomedical Science·Kovit PattanapanyasatNattawat Onlamoon
Oct 8, 2019·Human Vaccines & Immunotherapeutics·Stephen J Thomas, In-Kyu Yoon

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
ELISAs
FCS

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.